This site uses cookies, including third-party cookies, that help us to provide and improve our services.

Privacy Policy
- Global Locations -
Headquarters
Future Market Insights, Inc.
Christiana Corporate, 200 Continental Drive, Suite 401, Newark, Delaware - 19713, United States
T: +1-845-579-5705
MEA
Market Access DMCC
1602-6 Jumeirah Bay X2 Tower, Plot No: JLT-PH2-X2A,
Jumeirah Lakes Towers, Dubai,
United Arab Emirates
Americas
Future Market Insights
616 Corporate Way, Suite 2-9018,
Valley Cottage, NY 10989,
United States
T: +1-347-918-3531
Europe
Future Market Insights
3rd Floor, 207 Regent Street,
London W1B 3HH
United Kingdom
T: + 44 (0) 20 8123 9659
D: +44 (0) 20 3287 4268
APAC
Future Market Insights
Office No. 401-A, 4th Floor,
VANTAGE 9, S.No. 36/1/1,
Baner, Pune 411045 India

Cancer Diagnostics Market

Cancer Diagnostics to take a turn for the better, thanks to incorporation of AI and other Smart Technologies

Cancer Diagnostics Market by Test Type, Indication, End Use, Region & Forecast 2022 to 2032

Cancer Diagnostics Market Snapshot (2022 to 2032)

[285 Pages Report] The global cancer diagnostics market is projected to expand steadily at a CAGR 7.1% value, during the forecast period 2022 to 2032. In the year 2022, the market size is projected to expand and gain a global market valuation of US$ 191 Billion. Considering this increasing growth and demand in the global market, the cancer diagnostics market is expected to reach US$ 379 Billion by 2032.

Cancer is among the top causes of mortality worldwide, and its incidence is increasing at an alarming rate. As a result, healthcare experts are concentrating on the development of efficient treatment and diagnosis solutions in order to reduce the incidence level. Early detection improves treatment regimen success rates. As a consequence, healthcare institutions and industry companies are pushing routine exams through different awareness efforts.

Data Points

Key Statistics

Global Growth Rate (2022 to 2032)

7.1% CAGR

Cancer Diagnostics Market Value 2022

US$ 191 Billion

Cancer Diagnostics Market Projected Value (2032)

US$ 379 Billion

Increases in the prevalence and incidence of different forms of cancer, such as lung cancer and breast cancer, will boost the cancer diagnostics market over the projected period. Furthermore, a spike in technical improvements supporting the improved imaging of dangerous cells, innovations in equipment to detect the kind of cancer, and an increase in the accuracy of the result would assist the cancer diagnostics market in gaining momentum throughout the projection period. Increased government activities and other private groups to raise awareness about early cancer identification and prevention are expected to drive market expansion in the future years.

Furthermore, increased diagnostics laboratory infrastructure in developed nations is projected to drive the market in the coming years. During the predicted period, there will be a significant increase in emphasis on health and safety laws, as well as a boom in popularity of yoga and other health-related practices. However, the high cost of diagnostic imaging systems and the development of diverse diagnostic techniques for distinct cancer mutations may stymie market expansion.

Customize this Report

Let us know your requirement to get
100% FREE customization

2017 to 2021 Cancer Diagnostics Market Demand Analysis vs. Forecast 2022 to 2032

According to market research and competitive intelligence provider Future Market Insights- the market for cancer diagnostics reflected a value of 5.9% during the historical period, 2017 to 2021. National lockdown, government controls, and a spike in infection rates across countries all had a major financial impact on neurological clinics and hospitals. Several clinics and hospitals have seen a decrease in patient visits as a result of COVID-19, thereby minimizing client engagement.

Furthermore, many cancer diagnoses have been pushed back as a result of the COVID-19 dilemma. There was a global shortage of medical treatment for disorders other than COVID-19, which has had a detrimental influence on the cancer diagnostics business. Also, the restricted availability of healthcare personnel throughout the world is another aspect that has a negative impact on the cancer diagnostics industry.

However, post the pandemic, the complication in various people have increased. People suffering from even stage 1 cancer faced complications as the effects of the virus affected the immune system gravely. This paced up the demand for various drugs and also made the companies to expand the product portfolio to provide enhanced immunity to the patients. As a result the demand is expected to go over 7% CAGR during the forecast period.

Prominent Growth Drivers Influencing Cancer Diagnostics Market

Increasing use of AI to boost the demand of Cancer Diagnostics

The usage of AI in cancer detection is also predicted to boost market growth. AI technologies have been created by scientists to help screening tests for several types of cancer, particularly breast cancer. For more than 20 years, AI-based computer algorithms have been used to assist clinicians in interpreting mammograms, but research in this field is rapidly expanding.

For example, Freenome, a United States based AI genomics startup, is focusing on creating blood tests that utilize Artificial Intelegence to detect the body's early-warning indications of cancer. In October 2018, the business revealed preliminary findings from research and development for applying machine learning to identify colorectal cancer in its early stages.

The NCI's Center for Cancer Research, for example, built an AI model that might help radiologists identify possibly aggressive prostate cancer on a relatively new type of prostate MRI scan called multiparametric MRI. As a result, such achievements are projected to move the company forward in the worldwide market.

Establishment of Private Diagnostic Centers to aid Cancer Diagnostics Market Growth

The amount of private diagnostic centers is expanding across the world as the demand for diagnostic imaging operations rises and the load on public hospitals grows due to the restricted number of imaging techniques available. In January 2021, FUJIFILM Corporation established NURA, a cancer screening medical screening center in Bangalore, India. FUJIFILM DKH LLP (FUJIFILM DKH) and Dr. Kutty's Healthcare run this medical screening center (DKH). FUJIFILM DKH LLP (FUJIFILM DKH) is a FUJIFILM and Dr. Kutty's Healthcare (DKH) joint venture that operates hospitals and screening facilities throughout India and the Middle East.

Various centers are also working on liquid biopsy and animal cancer therapies at the same time. The advancement of biopsy platforms for companion animal malignancies is likely to provide profitable growth prospects for global cancer diagnostics market participants.

For example, Zomedica Pharmaceuticals Corp., a veterinary diagnostic and pharmaceutical business, stated in January 2020 that it has completed the development and manufacture of their reference lab cancer liquid biopsy platform for canine malignancies. These advanced developments in this field are expected to accelerate the global cancer diagnostics market during the forecast period.

Sabyasachi Ghosh
Sabyasachi Ghosh
Principal Consultant
LinkedIn
Talk to Analyst

Find your sweet spots for generating winning opportunities in this market.

Talk to Analyst

What could Possibly Hinder Cancer Diagnostics Market Demand?

Poor Reimbursement Policies and Higher Cost will restrict Market Growth

Inadequate reimbursement regulations are predicted to stymie market expansion. In recent years, there have been several developments in radiology in terms of imaging equipment. However, most medical insurance companies do not cover procedures that use computer-aided detection (CAD). As a consequence, individuals choose traditional diagnostic methods such as biopsies, pathology tests, or conventional imaging methods such as mammography and MRI treatments.

Furthermore, the high cost of cancer detection software is projected to stifle market expansion. Computer-aided Detection (CAD) software comes with a one-year license, which hospitals must renew each year. Furthermore, some insurance companies are opting out of CAD procedure reimbursement since it is judged excessive and not recommended by senior radiologists. Such hindrances will affect the global market during the forecast period.

Category-wise Insights

Which Test Type is forecast to gain the Maximum Market Share?

The Imaging Segment will dominate the segment during the Forecast Period

With a 58% market share in 2021, the imaging category led the market and is likely to retain its dominance throughout the forecast period. Modalities used in imaging like computed Tomography (CT) scans and Magnetic Resonance Imaging (MRI) are rapid, non-invasive, and painless diagnostic methods.

Imaging aids in cancer staging, as do prognostic and therapy system monitoring of metabolic and functional information. Due to these advantages, the use of imaging modalities in cancer screening programmes has significantly grown. Globally, the use of sophisticated imaging tests including such as multiphoton microscopy and magnetic resonance imaging is increasing.

The various imaging modalities, in conjunction with other genetic and laboratory testing, are employed as supporting tests in detecting a range of cancer forms, aiding in the selection of a suitable treatment strategy. These factors are expected to propel the imaging segment at an 8.0% CAGR throughout the forecast period.

Which Indication Segment will gain the larger share during The Forecast Period?

Breast Cancer Indication to gain significance during the forecast period

In 2021, the breast cancer sector held the major portion of the cancer diagnostics market, accounting for Mammography has become the most frequent and widely used screening technique 34.0%. for breast tumors.

Women between the ages of 50 and 74 are at a greater risk of getting breast cancer, according to the United States Preventive Services Task Force (USPSTF). As a result, the USPSTF advises that women over the age of 40 have mammography done every two years.

Furthermore, several organizations, such as the National Breast Cancer Foundation, Inc., are launching campaigns to raise awareness about breast cancer, the benefits of early detection, and available treatment choices. Increased public awareness, along with campaigns supporting routine mammography, is driving rising demand for scanning solutions in breast cancer detection.

MarketNage
Become a MarketNgage Insider

A unified Market Research Subscription Platform, built for today's disparate research needs.

Region-wise Analysis

What is the outlook of the North American Cancer Diagnostics Market?

Presence of various medical firms will boost the market demand for cancer diagnostics

In terms of market share and revenue, the North American market is predicted to be the most lucrative market for cancer diagnostics during the forecast period, 2022 and 2032. In 2021, the regional cancer diagnostics market boomed with a revenue share of 45%

One of the primary factors propelling the diagnostics industry in the region is the presence of various biotechnology and medical device firms. North America is likely to maintain its lead during the projection period due to factors such as increased spending for R&D initiatives and widespread use of new technology.

Furthermore, the region's high concentration of important players, growing FDA approvals, strategic partnerships, and substantial expenditure in research & development activities are projected to enhance the market. Merck & Co. Inc, for example, entered into a formal agreement in November 2020 to purchase Velosbio Inc., a privately owned clinical-stage biopharmaceutical firm dedicated to developing first-in-class cancer medicines targeting the receptor tyrosine kinase-like orphan receptor 1. (ROR1). Such advancements will make the demand stronger in this region during the forecast period.

How is the growth of the cancer diagnostics market emerging in the Asia Pacific?

Increasing cancer incidences and low treatment rates will boost the demand in this region

During the projection period, Asia Pacific is expected to grow at a CAGR of 6.9%. In the coming years, the Asia Pacific area is expected to be one of the emerging economies for cancer diagnostics.

Due to the existence of a big patient pool, the availability of experienced technicians at a reduced cost, and a clear regulatory environment encouraging quicker product approvals, Asia Pacific is likely to display the strongest growth in the near future. Furthermore, the burgeoning medical tourism business in countries like China, India, and Malaysia is likely to increase demand for cancer diagnosis and treatment screening.

East Asia's growth rate is predicted to accelerate. According to the World Health Organization, approximately 4.7 million new cancer cases will be diagnosed in China by 2025. Obesity and hormone exposure-related malignancies, such as breast cancer in women, and "lifestyle change-related diseases," such as prostate cancer in men, are on the rise in China, resulting in increased use of cancer diagnostics. These incidents will boost the regional growth for cancer diagnostics.

What will be the outlook of the European cancer diagnostics market during the forecast period?

Desirable policies and growing diagnostic centers will accelerate the demand

The European cancer diagnostics market is predicted to increase significantly throughout the forecast period, with a CAGR of 5.2% during 2022-2032.

Desirable healthcare policies, along with high average per capita healthcare costs, have produced a favorable climate in the United Kingdom for the adoption of modern cancer diagnostic technology such as imaging. In addition, the existence of major players promotes expansion in the United Kingdom. These firms' strategies include new releases and growth initiatives, which will continue to help overall expansion in Europe.

Start-up Scenario

  • Race Oncology is an ASX-listed precise oncology firm that is developing Zantrene®, a Phase 2/3 cancer medication. Zantrene® is a powerful fatso/fat mass and obesity linked (FTO) protein inhibitor. Overexpression of FTO has been identified as a genetic driver of a variety of malignancies. Race is investigating the potential of Zantrene® as a novel treatment for melanoma and clear cell renal cell carcinoma, two malignancies that frequently over-express FTO. In groundbreaking preclinical research, Race revealed that Zantrene® protects against anthracycline-induced heart damage while also functioning in combination with anthracyclines to boost their capacity to target breast cancer. Race is assessing this discovery.
  • Carer, which was founded in 2018, aims to improve the quality of life of every cancer patient in the convenience of their own home. It attempts to give patients with the best degree of support and therapy both during and after treatment to help recovery. Their therapy has a significant benefit in that it can be tailored to each patient's diagnosis, prior health difficulties, and chosen lifestyle, making it more feasible in the long run. This is accomplished through their three-pronged approach, which includes a dietary protocol, a movement and meditation protocol, and a mental well-being protocol which educates and motivates patients and caregivers to make life-changing adjustments for more successful healing.

Competitive Landscape

The adoption of novel goods and their significant R&D efforts to offer developments in the same have helped major companies operating in the sector maintain a strong position in the worldwide market. The market's competition is projected to heat up in the near future, as numerous businesses are focusing their efforts on research and the introduction of novel diagnostic procedures through product line expansions and acquisitions and mergers.

  • Gland Pharma has launched the cancer treatment medicine Bortezomib for Injection in the United States in 2022. The drug business stated in a statement that it has released the medicine in the United States market through a partner who has acquired permission from the United States Food and Drug Administration (USFDA). The business claims that its medicine is medically similar to Velcade for Injection from Takeda Pharmaceuticals. Bortezomib for Intravenous is used to treat cancers such as myeloma and mantle cell lymphoma.
  • Bristol-Myers Squibb K.K. announced in 2022 that the Japanese Ministry of Health, Labour, and Welfare had approved Abecma (idecabtagene vicleucel), a B-cell maturation antigen (BCMA)-directed chimeric antigen receptor (CAR) T cell immunotherapy, for the the treatment of adult patients with refractory or relapsed (R/R) multiple myeloma who had received a minimum of three prior therapies. In Japan, Abecma was the first CAR T cell therapy licensed for treating R/R multiple myeloma in 2021. In Japan, Abecma is the first CAR T cell therapy licensed for treating R/R multiple myeloma in 2021. Bristol Myers Squibb is currently the only firm in Japan with two authorized CAR T cell therapies: the CD19-directed Breyanzi, which was approved in March 2021, and the BCMA-directed Abecma.

Report Scope

Report Attribute

Details

Growth Rate

CAGR of 7.1% from 2022 to 2032

Market Value for 2022

US$ 191 Billion

Market Value for 2032

US$ 379 Billion

Base Year for Estimation

2021

Historical Data

2017 to 2021

Forecast Period

2022 to 2032

Quantitative Units

US$ Billion for Value

Report Coverage

Revenue Forecast, Company Ranking, Competitive Landscape, Growth Factors, Trends and Pricing Analysis

Segments Covered

  • Test Type
  • Indication
  • End User
  • Region

Regions Covered

  • North America
  • Latin America
  • Europe
  • East Asia
  • South Asia
  • Oceania
  • Middle East & Africa

Key Countries Profiled

  • United States
  • Canada
  • Brazil
  • Mexico
  • Germany
  • United Kingdom
  • France
  • Spain
  • Italy
  • China
  • Japan
  • South Korea
  • Malaysia
  • Singapore
  • Australia
  • New Zealand
  • Gulf Cooperation Council Countries
  • South Africa
  • Israel

Key Companies Profiled

  • Abbott Laboratories
  • Roche Holding AG
  • Thermo Fisher Scientific Inc.
  • Siemens AG
  • Bio Rad Laboratories Inc.
  • GE Healthcare
  • Illumina, Inc.
  • Bristol-Myers Squibb
  • Koninklijke Philips N.V.
  • Toshiba Medical Systems Corporation
  • Agilent Technologies Inc.

Report Customization & Pricing

Available upon Request

Key Segments Covered In the Cancer Diagnostics Market Report

Cancer Diagnostics Market by Test Type:

  • Tumor Biomarkers Tests
    • PSA Tests
    • CTC Tests
    • AFP Tests
    • CA Tests
    • HER2 Tests
    • BRCA Tests
    • ALK Tests
    • CEA Tests
    • EGFR Mutation Tests
    • KRAS Mutation Tests
    • Others
  • Imaging
    • Ultrasound
    • Mammography
    • MRI Scan
    • PET Scan
    • CT Scan
    • SPECT & Others
  • Biopsy
    • Needle Biopsy
    • Endoscopic Biopsy
    • Bone Marrow Biopsy
    • Others
  • Liquid Biopsy
  • Immunohistochemistry
  • In Situ Hybridization

Cancer Diagnostics Market by Indication:

  • Breast Cancer
  • Lung Cancer
  • Colorectal Cancer
  • Melanoma
  • Blood Cancer
  • Prostate Cancer
  • Ovarian Cancer
  • Stomach Cancer
  • Liver Cancer
  • Others

Cancer Diagnostics Market by End User:

  • Hospital Associated Labs
  • Independent Diagnostic Laboratories
  • Diagnostic Imaging Centers
  • Cancer Research Institutes
  • Others

Cancer Diagnostics Market by Region:

  • North America
  • Latin America
  • Europe
  • East Asia
  • South Asia
  • Oceania
  • Middle East & Africa (MEA)

Frequently Asked Questions

From 2017-2021, the cancer diagnostics market grew at a CAGR of 5.9%

The global cancer diagnostics market is expected to grow with a 7.1% CAGR during 2022-2032.

As of 2032, the cancer diagnostics market is expected to reach US$ 379 Billion

In 2021, the imaging category by test type occupied a 58% market share and is expected to dominate the global market in 2022 too.

By indication, the breast segment held a global market share of 38% in 2021.

The North American cancer diagnostics market was projected to gain a global market share of 45% in 2021.

Asia Pacific is expected to grow steadily with a CAGR of 6.9% during 2022-2032.

During the forecast period, the European market for cancer diagnostics will exhibit a 5.2% CAGR.

Table of Content

1. Executive Summary

    1.1. Global Market Outlook

    1.2. Demand Side Trends

    1.3. Supply Side Trends

    1.4. Analysis and Recommendations

2. Market Overview

    2.1. Market Coverage / Taxonomy

    2.2. Market Definition / Scope / Limitations

    2.3. Market Dynamics

    2.4. Inclusions and Exclusions

3. Market Background

    3.1. Macro-Economic Factors

        3.1.1. Global GDP Growth Outlook

        3.1.2. Global Healthcare Expenditure Outlook

        3.1.3. Growth of Healthcare Sector in Emerging Nations

    3.2. Forecast Factors - Relevance & Impact

        3.2.1. Global Increase in Healthcare Expenditure

        3.2.2. Rising Prevalence of Cancer

        3.2.3. Changing Regulatory Dynamics

        3.2.4. Cost Impact

        3.2.5. Regulatory Scenario

    3.3. Market Dynamics

        3.3.1. Drivers

        3.3.2. Restraints

        3.3.3. Opportunity Analysis

4. Market Context

    4.1. Key Industry Developments

    4.2. Disease Epidemiology

    4.3. Regulatory and Reimbursement Scenario

    4.4. Strategic Promotional Strategies by Manufacturer

5. COVID19 Crisis Impact Analysis

        5.1.1. Current perspectives on the Coronavirus outbreak

        5.1.2. Current GDP Projection and Probable Impact

        5.1.3. Current Economic Projection as compared to 2008 Economic analysis

        5.1.4. COVID19 and Impact Analysis

    5.2. Market Revenue Impact Analysis

        5.2.1. Historical (pre-COVID), Current (during-COVID), Future (post-COVID)

            5.2.1.1. By Test Type

            5.2.1.2. By Indication

            5.2.1.3. By End User

            5.2.1.4. By Region

        5.2.2. 2020 Market Scenario

    5.3. Impact on Trends Analysis

    5.4. Recovery Scenario – Short term, Midterm and Long Term Impact

6. Global Market Value (US$ Mn) Analysis 2017-2021 and Forecast, 2021–2031

    6.1. Historical Market Value (US$ Mn) Analysis, 2017-2021

    6.2. Current and Future Market Value (US$ Mn) Projections, 2022-2032

        6.2.1. Y-o-Y Growth Trend Analysis

        6.2.2. Absolute $ Opportunity Analysis

7. Global Market Analysis 2017-2021 and Forecast 2022-2032, By Test Type

    7.1. Introduction / Key Findings

    7.2. Historical Market Size (US$ Mn) Analysis By Test Type, 2017-2021

    7.3. Current and Future Market Size (US$ Mn) Analysis and Forecast, By Test Type, 2022-2032

        7.3.1. Tumor Biomarkers Tests

            7.3.1.1. PSA Tests

            7.3.1.2. CTC Tests

            7.3.1.3. AFP Tests

            7.3.1.4. CA Tests

            7.3.1.5. HER2 Tests

            7.3.1.6. BRCA Tests

            7.3.1.7. ALK Tests

            7.3.1.8. CEA Tests

            7.3.1.9. EGFR Mutation Tests

            7.3.1.10. KRAS Mutation Tests

            7.3.1.11. Others

        7.3.2. Imaging

            7.3.2.1. Ultrasound

            7.3.2.2. Mammography

            7.3.2.3. MRI Scan

            7.3.2.4. PET Scan

            7.3.2.5. CT Scan

            7.3.2.6. SPECT & Others

        7.3.3. Biopsy

            7.3.3.1. Needle Biopsy

            7.3.3.2. Endoscopic Biopsy

            7.3.3.3. Bone Marrow Biopsy

            7.3.3.4. Others

        7.3.4. Liquid Biopsy

        7.3.5. Immunohistochemistry

        7.3.6. In Situ Hybridization

    7.4. Market Attractiveness Analysis By Test Type

8. Global Market Analysis 2017-2021 and Forecast 2022-2032, By Indication

    8.1. Introduction / Key Findings

    8.2. Historical Market Size (US$ Mn) Analysis By Indication, 2017-2021

    8.3. Current and Future Market Size (US$ Mn) Analysis and Forecast By Indication, 2022-2032

        8.3.1. Breast Cancer

        8.3.2. Lung Cancer

        8.3.3. Colorectal Cancer

        8.3.4. Melanoma

        8.3.5. Blood Cancer

        8.3.6. Prostate Cancer

        8.3.7. Ovarian Cancer

        8.3.8. Stomach Cancer

        8.3.9. Liver Cancer

        8.3.10. Others

    8.4. Market Attractiveness Analysis By Indication

9. Global Market Analysis 2017-2021 and Forecast 2022-2032, By End User

    9.1. Introduction / Key Findings

    9.2. Historical Market Size (US$ Mn) Analysis By End User, 2017-2021

    9.3. Current and Future Market Size (US$ Mn) Analysis and Forecast By End User, 2022-2032

        9.3.1. Hospital Associated Labs

        9.3.2. Independent Diagnostic Laboratories

        9.3.3. Diagnostic Imaging Centers

        9.3.4. Cancer Research Institutes

        9.3.5. Others

    9.4. Market Attractiveness Analysis By End User

10. Global Market Analysis 2017-2021 and Forecast 2022-2032, by Region

    10.1. Introduction

    10.2. Historical Market Size (US$ Mn) Analysis By Region, 2017-2021

    10.3. Current and Future Market Size (US$ Mn) Analysis By Market Taxonomy, 2022-2032

        10.3.1. North America

        10.3.2. Latin America

        10.3.3. Europe

        10.3.4. East Asia

        10.3.5. South Asia

        10.3.6. Oceania

        10.3.7. Middle East and Africa (MEA)

    10.4. Market Attractiveness Analysis By Region

11. North America Market Analysis 2017-2021 and Forecast 2022-2032

    11.1. Introduction

    11.2. Historical Market Size (US$ Mn) Analysis By Market Taxonomy, 2017-2021

    11.3. Current and Future Market Size (US$ Mn) Analysis By Market Taxonomy, 2022-2032

        11.3.1. By Country

            11.3.1.1. U.S.

            11.3.1.2. Canada

        11.3.2. By Test Type

        11.3.3. By Indication

        11.3.4. By End User

    11.4. Market Attractiveness Analysis

    11.5. Key Market Participants - Intensity Mapping

    11.6. Drivers and Restraints - Impact Analysis

12. Latin America Market Analysis 2017-2021 and Forecast 2022-2032

    12.1. Introduction

    12.2. Historical Market Size (US$ Mn) Analysis By Market Taxonomy, 2017-2021

    12.3. Current and Future Market Size (US$ Mn) Analysis By Market Taxonomy, 2022-2032

        12.3.1. By Country

            12.3.1.1. Brazil

            12.3.1.2. Mexico

            12.3.1.3. Argentina

            12.3.1.4. Rest of Latin America

        12.3.2. By Test Type

        12.3.3. By Indication

        12.3.4. By End User

    12.4. Market Attractiveness Analysis

    12.5. Key Market Participants - Intensity Mapping

    12.6. Drivers and Restraints - Impact Analysis

13. Europe Market Analysis 2017-2021 and Forecast 2022-2032

    13.1. Introduction

    13.2. Historical Market Size (US$ Mn) Analysis By Market Taxonomy, 2017-2021

    13.3. Current and Future Market Size (US$ Mn) Analysis By Market Taxonomy, 2022-2032

        13.3.1. By Country

            13.3.1.1. Germany

            13.3.1.2. Italy

            13.3.1.3. France

            13.3.1.4. U.K.

            13.3.1.5. Spain

            13.3.1.6. BENELUX

            13.3.1.7. Russia

            13.3.1.8. Rest of Europe

        13.3.2. By Test Type

        13.3.3. By Indication

        13.3.4. By End User

    13.4. Market Attractiveness Analysis

    13.5. Key Market Participants - Intensity Mapping

    13.6. Drivers and Restraints - Impact Analysis

14. South Asia Market Analysis 2017-2021 and Forecast 2022-2032

    14.1. Introduction

    14.2. Historical Market Size (US$ Mn) Analysis By Market Taxonomy, 2017-2021

    14.3. Current and Future Market Size (US$ Mn) Analysis By Market Taxonomy, 2022-2032

        14.3.1. By Country

            14.3.1.1. India

            14.3.1.2. Thailand

            14.3.1.3. Indonesia

            14.3.1.4. Malaysia

            14.3.1.5. Rest of South Asia

        14.3.2. By Test Type

        14.3.3. By Indication

        14.3.4. By End User

    14.4. Market Attractiveness Analysis

    14.5. Key Market Participants - Intensity Mapping

    14.6. Drivers and Restraints - Impact Analysis

15. East Asia Market Analysis 2017-2021 and Forecast 2022-2032

    15.1. Introduction

    15.2. Historical Market Size (US$ Mn) Analysis By Market Taxonomy, 2017-2021

    15.3. Current and Future Market Size (US$ Mn) Analysis By Market Taxonomy, 2022-2032

        15.3.1. By Country

            15.3.1.1. China

            15.3.1.2. Japan

            15.3.1.3. South Korea

        15.3.2. By Test Type

        15.3.3. By Indication

        15.3.4. By End User

    15.4. Market Attractiveness Analysis

    15.5. Key Market Participants - Intensity Mapping

    15.6. Drivers and Restraints - Impact Analysis

16. Oceania Market Analysis 2017-2021 and Forecast 2022-2032

    16.1. Introduction

    16.2. Historical Market Size (US$ Mn) Analysis By Market Taxonomy, 2017-2021

    16.3. Current and Future Market Size (US$ Mn) Analysis By Market Taxonomy, 2022-2032

        16.3.1. By Country

            16.3.1.1. Australia

            16.3.1.2. New Zealand

        16.3.2. By Test Type

        16.3.3. By Indication

        16.3.4. By End User

    16.4. Market Attractiveness Analysis

    16.5. Key Market Participants - Intensity Mapping

    16.6. Drivers and Restraints - Impact Analysis

17. Middle East and Africa Market Analysis 2017-2021 and Forecast 2022-2032

    17.1. Introduction

    17.2. Historical Market Size (US$ Mn) Analysis By Market Taxonomy, 2017-2021

    17.3. Current and Future Market Size (US$ Mn) Analysis By Market Taxonomy, 2022-2032

        17.3.1. By Country

            17.3.1.1. GCC Countries

            17.3.1.2. South Africa

            17.3.1.3. Rest of Middle East and Africa

        17.3.2. By Test Type

        17.3.3. By Indication

        17.3.4. By End User

    17.4. Market Attractiveness Analysis

    17.5. Key Market Participants - Intensity Mapping

    17.6. Drivers and Restraints - Impact Analysis

18. Key and Emerging Countries Market Analysis 2017-2021 and Forecast 2022-2032

    18.1. Introduction

        18.1.1. Market Value Proportion Analysis, By Key Countries

        18.1.2. Global Vs. Country Growth Comparison

    18.2. U.S. Market Analysis

        18.2.1. By Test Type

        18.2.2. By Indication

        18.2.3. By End User

    18.3. Canada Market Analysis

        18.3.1. By Test Type

        18.3.2. By Indication

        18.3.3. By End User

    18.4. Mexico Market Analysis

        18.4.1. By Test Type

        18.4.2. By Indication

        18.4.3. By End User

    18.5. Brazil Market Analysis

        18.5.1. By Test Type

        18.5.2. By Application

        18.5.3. By Indication

        18.5.4. By End User

    18.6. U.K. Market Analysis

        18.6.1. By Test Type

        18.6.2. By Indication

        18.6.3. By End User

    18.7. Germany Market Analysis

        18.7.1. By Test Type

        18.7.2. By Indication

        18.7.3. By End User

    18.8. France Market Analysis

        18.8.1. By Test Type

        18.8.2. By Indication

        18.8.3. By End User

    18.9. Italy Market Analysis

        18.9.1. By Test Type

        18.9.2. By Indication

        18.9.3. By End User

    18.10. France Market Analysis

        18.10.1. By Test Type

        18.10.2. By Indication

        18.10.3. By End User

    18.11. Spain Market Analysis

        18.11.1. By Test Type

        18.11.2. By Indication

        18.11.3. By End User

    18.12. Russia Market Analysis

        18.12.1. By Test Type

        18.12.2. By Indication

        18.12.3. By End User

    18.13. Poland Market Analysis

        18.13.1. By Test Type

        18.13.2. By Indication

        18.13.3. By End User

    18.14. China Market Analysis

        18.14.1. By Test Type

        18.14.2. By Indication

        18.14.3. By End User

    18.15. Japan Market Analysis

        18.15.1. By Test Type

        18.15.2. By Indication

        18.15.3. By End User

    18.16. South Korea Market Analysis

        18.16.1. By Test Type

        18.16.2. By Indication

        18.16.3. By End User

    18.17. India Market Analysis

        18.17.1. By Test Type

        18.17.2. By Indication

        18.17.3. By End User

    18.18. Thailand Market Analysis

        18.18.1. By Test Type

        18.18.2. By Indication

        18.18.3. By End User

    18.19. Indonesia Market Analysis

        18.19.1. By Test Type

        18.19.2. By Indication

        18.19.3. By End User

    18.20. Malaysia Market Analysis

        18.20.1. By Test Type

        18.20.2. By Indication

        18.20.3. By End User

    18.21. Australia Market Analysis

        18.21.1. By Test Type

        18.21.2. By Indication

        18.21.3. By End User

    18.22. New Zealand Market Analysis

        18.22.1. By Test Type

        18.22.2. By Indication

        18.22.3. By End User

    18.23. GCC Countries Market Analysis

        18.23.1. By Test Type

        18.23.2. By Indication

        18.23.3. By End User

    18.24. Turkey Market Analysis

        18.24.1. By Test Type

        18.24.2. By Indication

        18.24.3. By End User

    18.25. South Africa Market Analysis

        18.25.1. By Test Type

        18.25.2. By Indication

        18.25.3. By End User

19. Market Structure Analysis

    19.1. Market Analysis by Tier of Companies

    19.2. Market Share Analysis of Top Players

    19.3. Market Concentration

    19.4. Competition Benchmarking

    19.5. Market Presence Analysis

        19.5.1. Regional Footprint by Players

        19.5.2. Product Foot print by Players

        19.5.3. Channel Foot Print by Players

20. Competition Analysis

    20.1. Competition Dashboard

    20.2. Competition Deep Dive (Tentative List)

        20.2.1. Abbott Laboratories

            20.2.1.1. Overview

            20.2.1.2. Product Portfolio

            20.2.1.3. Profitability by Market Segments (Product/Channel/Region)

            20.2.1.4. Sales Footprint

            20.2.1.5. Strategy Overview

                20.2.1.5.1. Marketing Strategy

                20.2.1.5.2. Product Strategy

                20.2.1.5.3. Channel Strategy

        20.2.2. Roche Holding AG

            20.2.2.1. Overview

            20.2.2.2. Product Portfolio

            20.2.2.3. Profitability by Market Segments (Product/Channel/Region)

            20.2.2.4. Sales Footprint

            20.2.2.5. Strategy Overview

                20.2.2.5.1. Marketing Strategy

                20.2.2.5.2. Product Strategy

                20.2.2.5.3. Channel Strategy

        20.2.3. Thermo Fisher Scientific Inc.

            20.2.3.1. Overview

            20.2.3.2. Product Portfolio

            20.2.3.3. Profitability by Market Segments (Product/Channel/Region)

            20.2.3.4. Sales Footprint

            20.2.3.5. Strategy Overview

                20.2.3.5.1. Marketing Strategy

                20.2.3.5.2. Product Strategy

                20.2.3.5.3. Channel Strategy

        20.2.4. Siemens AG

            20.2.4.1. Overview

            20.2.4.2. Product Portfolio

            20.2.4.3. Profitability by Market Segments (Product/Channel/Region)

            20.2.4.4. Sales Footprint

            20.2.4.5. Strategy Overview

                20.2.4.5.1. Marketing Strategy

                20.2.4.5.2. Product Strategy

                20.2.4.5.3. Channel Strategy

        20.2.5. Bio Rad Laboratories Inc

            20.2.5.1. Overview

            20.2.5.2. Product Portfolio

            20.2.5.3. Profitability by Market Segments (Product/Channel/Region)

            20.2.5.4. Sales Footprint

            20.2.5.5. Strategy Overview

                20.2.5.5.1. Marketing Strategy

                20.2.5.5.2. Product Strategy

                20.2.5.5.3. Channel Strategy

        20.2.6. GE Healthcare

            20.2.6.1. Overview

            20.2.6.2. Product Portfolio

            20.2.6.3. Profitability by Market Segments (Product/Channel/Region)

            20.2.6.4. Sales Footprint

            20.2.6.5. Strategy Overview

                20.2.6.5.1. Marketing Strategy

                20.2.6.5.2. Product Strategy

                20.2.6.5.3. Channel Strategy

        20.2.7. Illumina, Inc

            20.2.7.1. Overview

            20.2.7.2. Product Portfolio

            20.2.7.3. Profitability by Market Segments (Product/Channel/Region)

            20.2.7.4. Sales Footprint

            20.2.7.5. Strategy Overview

                20.2.7.5.1. Marketing Strategy

                20.2.7.5.2. Product Strategy

                20.2.7.5.3. Channel Strategy

        20.2.8. Koninklijke Philips N.V.

            20.2.8.1. Overview

            20.2.8.2. Product Portfolio

            20.2.8.3. Profitability by Market Segments (Product/Channel/Region)

            20.2.8.4. Sales Footprint

            20.2.8.5. Strategy Overview

                20.2.8.5.1. Marketing Strategy

                20.2.8.5.2. Product Strategy

                20.2.8.5.3. Channel Strategy

        20.2.9. Toshiba Medical Systems Corporation

            20.2.9.1. Overview

            20.2.9.2. Product Portfolio

            20.2.9.3. Profitability by Market Segments (Product/Channel/Region)

            20.2.9.4. Sales Footprint

            20.2.9.5. Strategy Overview

                20.2.9.5.1. Marketing Strategy

                20.2.9.5.2. Product Strategy

                20.2.9.5.3. Channel Strategy

        20.2.10. Agilent Technologies, Inc.

            20.2.10.1. Overview

            20.2.10.2. Product Portfolio

            20.2.10.3. Profitability by Market Segments (Product/Channel/Region)

            20.2.10.4. Sales Footprint

            20.2.10.5. Strategy Overview

                20.2.10.5.1. Marketing Strategy

                20.2.10.5.2. Product Strategy

                20.2.10.5.3. Channel Strategy

21. Assumptions and Acronyms Used

22. Research Methodology

Customize this Report

Let us know your requirement to get
100% FREE customization

List of Tables

Table 01: Global Market Value (US$ Mn) Analysis and Opportunity Assessment 2016–2031, By Test Type

Table 02: Global Market Value (US$ Mn) Analysis and Opportunity Assessment 2016-2031, By Indication

Table 03: Global Market Value (US$ Mn) Analysis and Opportunity Assessment 2016-2031, By End User

Table 04: Global Market Value (US$ Mn) Analysis and Opportunity Assessment 2016-2031, By Region

Table 05: North America Market Value (US$ Mn) Analysis 2017-2021 and Forecast 2021–2031, By Country

Table 06: North America Market Value (US$ Mn) Analysis and Opportunity Assessment 2016-2031, By Test Type

Table 07: North America Market Value (US$ Mn) Analysis and Opportunity Assessment 2016-2031, By Indication

Table 08: North America Market Value (US$ Mn) Analysis and Opportunity Assessment 2016-2031, By End User

Table 09: Latin America Market Value (US$ Mn) Analysis 2017-2021 and Forecast 2021–2031, By Country

Table 10: Latin America Market Value (US$ Mn) Analysis and Opportunity Assessment 2016-2031, By Test Type

Table 11: Latin America Market Value (US$ Mn) Analysis and Opportunity Assessment 2016-2031, By Indication

Table 12: Latin America Market Value (US$ Mn) Analysis and Opportunity Assessment 2016-2031, By End User

Table 13: Europe Market Value (US$ Mn) Analysis 2017-2021 and Forecast 2021–2031, By Country

Table 14: Europe Market Value (US$ Mn) Analysis and Opportunity Assessment 2016-2031, By Test Type

Table 15: Europe Market Value (US$ Mn) Analysis and Opportunity Assessment 2016-2031, By Indication

Table 16: Europe Market Value (US$ Mn) Analysis and Opportunity Assessment 2016-2031, By End User

Table 17: South Asia Market Value (US$ Mn) Analysis 2017-2021 and Forecast 2021–2031, By Country

Table 18: South Asia Market Value (US$ Mn) Analysis and Opportunity Assessment 2016-2031, By Test Type

Table 19: South Asia Market Value (US$ Mn) Analysis and Opportunity Assessment 2016-2031, By Indication

Table 20: South Asia Market Value (US$ Mn) Analysis and Opportunity Assessment 2016-2031, By End User

Table 21: East Asia Market Value (US$ Mn) Analysis 2017-2021 and Forecast 2021–2031, By Country

Table 22: East Asia Market Value (US$ Mn) Analysis and Opportunity Assessment 2016-2031, By Test Type

Table 23: East Asia Market Value (US$ Mn) Analysis and Opportunity Assessment 2016-2031, By Indication

Table 24: East Asia Market Value (US$ Mn) Analysis and Opportunity Assessment 2016-2031, By End User

Table 25: Oceania Market Value (US$ Mn) Analysis 2017-2021 and Forecast 2021–2031, By Country

Table 26: Oceania Market Value (US$ Mn) Analysis and Opportunity Assessment 2016-2031, By Test Type

Table 27: Oceania Market Value (US$ Mn) Analysis and Opportunity Assessment 2016-2031, By Indication

Table 28: Oceania Market Value (US$ Mn) Analysis and Opportunity Assessment 2016-2031, By End User

Table 29: MEA Market Value (US$ Mn) Analysis 2017-2021 and Forecast 2021–2031, By Country

Table 30: MEA Market Value (US$ Mn) Analysis and Opportunity Assessment 2016-2031, By Test Type

Table 31: MEA Market Value (US$ Mn) Analysis and Opportunity Assessment 2016-2031, By Indication

Table 32: MEA Market Value (US$ Mn) Analysis and Opportunity Assessment 2016-2031, By End User

Sabyasachi Ghosh
Principal Consultant
LinkedIn
Talk to Analyst

Find your sweet spots for generating winning opportunities in this market.

Talk to Analyst

List of Charts

Figure 01: Global Market Value Analysis (US$ Mn), 2017-2021

Figure 02: Global Market Value Forecast (US$ Mn), 2022-2032

Figure 03: Global Market Absolute $ Opportunity, 2022-2032

Figure 04: Global Market Share Analysis (%),By Test Type, 2022-2032

Figure 05: Global Market Y-o-Y Analysis (%), By Test Type, 2022-2032

Figure 06: Global Market Attractiveness Analysis By Test Type, 2022-2032

Figure 07: Global Market Share Analysis (%), By Indication, 2022-2032

Figure 08: Global Market Y-o-Y Analysis (%), By Indication, 2022-2032

Figure 09: Global Market Attractiveness Analysis By Indication, 2022-2032

Figure 10: Global Market Share Analysis (%), By End User, 2022-2032

Figure 11: Global Market Y-o-Y Analysis (%), By End User, 2022-2032

Figure 12: Global Market Attractiveness Analysis by End User, 2022-2032

Figure 13: Global Market Share Analysis (%), By Region, 2022-2032

Figure 14: Global Market Y-o-Y Analysis (%), By Region, 2022-2032

Figure 15: Global Market Attractiveness Analysis by Region, 2022-2032

Figure 16: North America Market Value Share, By Test Type, 2021 (E)

Figure 17: North America Market Value Share, By Indication, 2021 (E)

Figure 18: North America Market Value Share, By End User, 2021 (E)

Figure 19: North America Market Value Share, By Country, 2021 (E)

Figure 20: North America Market Value Analysis (US$ Mn), 2017-2021

Figure 21: North America Market Value Forecast (US$ Mn), 2022-2032

Figure 22: North America Market Attractiveness Analysis By Test Type, 2022-2032

Figure 23: North America Market Attractiveness Analysis By Indication, 2022-2032

Figure 24: North America Market Attractiveness Analysis by End User, 2022-2032

Figure 25: North America Market Attractiveness Analysis by Country, 2022-2032

Figure 26: Latin America Market Value Share, By Test Type, 2021 (E)

Figure 27: Latin America Market Value Share, By Indication, 2021 (E)

Figure 28: Latin America Market Value Share, By End User, 2021 (E)

Figure 29: Latin America Market Value Share, By Country, 2021 (E)

Figure 30: Latin America Market Value Analysis (US$ Mn), 2017-2021

Figure 31: Latin America Market Value Forecast (US$ Mn), 2022-2032

Figure 32: Latin America Market Attractiveness Analysis By Test Type, 2022-2032

Figure 33: Latin America Market Attractiveness Analysis By Indication, 2022-2032

Figure 34: Latin America Market Attractiveness Analysis by End User, 2022-2032

Figure 35: Latin America Market Attractiveness Analysis by Country, 2022-2032

Figure 36: Europe Market Value Share, By Test Type, 2021 (E)

Figure 37: Europe Market Value Share, By Indication, 2021 (E)

Figure 38: Europe Market Value Share, By End User, 2021 (E)

Figure 39: Europe Market Value Share, By Country, 2021 (E)

Figure 40: Europe Market Value Analysis (US$ Mn), 2017-2021

Figure 41: Europe Market Value Forecast (US$ Mn), 2022-2032

Figure 42: Europe Market Attractiveness Analysis By Test Type , 2022-2032

Figure 43: Europe Market Attractiveness Analysis By Indication, 2022-2032

Figure 44: Europe Market Attractiveness Analysis by End User, 2022-2032

Figure 45: Europe Market Attractiveness Analysis by Country, 2022-2032

Figure 46: South Asia Market Value Share, By Test Type, 2021 (E)

Figure 47: South Asia Market Value Share, By Indication, 2021 (E)

Figure 48: South Asia Market Value Share, By End User, 2021 (E)

Figure 49: South Asia Market Value Share, By Country, 2021 (E)

Figure 50: South Asia Market Value Analysis (US$ Mn), 2017-2021

Figure 51: South Asia Market Value Forecast (US$ Mn), 2022-2032

Figure 52: South Asia Market Attractiveness Analysis By Test Type, 2022-2032

Figure 53: South Asia Market Attractiveness Analysis By Indication, 2022-2032

Figure 54: South Asia Market Attractiveness Analysis by End User, 2022-2032

Figure 55: South Asia Market Attractiveness Analysis by Country, 2022-2032

Figure 56: East Asia Market Value Share, By Test Type, 2021 (E)

Figure 57: East Asia Market Value Share, By Indication, 2021 (E)

Figure 58: East Asia Market Value Share, By End User, 2021 (E)

Figure 59: East Asia Market Value Share, By Country, 2021 (E)

Figure 60: East Asia Market Value Analysis (US$ Mn), 2017-2021

Figure 61: East Asia Market Value Forecast (US$ Mn), 2022-2032

Figure 62: East Asia Market Attractiveness Analysis By Test Type, 2022-2032

Figure 63: East Asia Market Attractiveness Analysis By Indication, 2022-2032

Figure 64: East Asia Market Attractiveness Analysis by End User, 2022-2032

Figure 65: East Asia Market Attractiveness Analysis by Country, 2022-2032

Figure 66: Oceania Market Value Share, By Test Type, 2021 (E)

Figure 67: Oceania Market Value Share, By Indication, 2021 (E)

Figure 68: Oceania Market Value Share, By End User, 2021 (E)

Figure 69: Oceania Market Value Share, By Country, 2021 (E)

Figure 70: Oceania Market Value Analysis (US$ Mn), 2017-2021

Figure 71: Oceania Market Value Forecast (US$ Mn), 2022-2032

Figure 72: Oceania Market Attractiveness Analysis By Test Type, 2022-2032

Figure 73: Oceania Market Attractiveness Analysis By Indication, 2022-2032

Figure 74: Oceania Market Attractiveness Analysis by End User, 2022-2032

Figure 75: Oceania Market Attractiveness Analysis by Country, 2022-2032

Figure 76: MEA Market Value Share, By Test Type, 2021 (E)

Figure 77: MEA Market Value Share, By Indication, 2021 (E)

Figure 78: MEA Market Value Share, By End User, 2021 (E)

Figure 79: MEA Market Value Share, By Country, 2021 (E)

Figure 80: MEA Market Value Analysis (US$ Mn), 2017-2021

Figure 81: MEA Market Value Forecast (US$ Mn), 2022-2032

Figure 82: MEA Market Attractiveness Analysis By Test Type, 2022-2032

Figure 83: MEA Market Attractiveness Analysis By Indication, 2022-2032

Figure 84: MEA Market Attractiveness Analysis by End User, 2022-2032

Figure 85: MEA Market Attractiveness Analysis by Country, 2022-2032

Figure 86: U.S. Market Share Analysis (%), By Test Type, 2022 & 2032

Figure 87: U.S. Market Share Analysis (%), By Indication, 2022 & 2032

Figure 88: U.S. Market Share Analysis (%), By End Users, 2022 & 2032

Figure 89: North America Vs. U.S. Growth Comparison

Figure 90: Canada Market Share Analysis (%), By Test Type, 2022 & 2032

Figure 91: Canada Market Share Analysis (%), By Indication, 2022 & 2032

Figure 92: Canada Market Share Analysis (%), By End Users, 2022 & 2032

Figure 93: North America Vs. Canada Growth Comparison

Figure 94: Brazil Market Share Analysis (%), By Test Type, 2022 & 2032

Figure 95: Brazil Market Share Analysis (%), By Indication, 2022 & 2032

Figure 96: Brazil Market Share Analysis (%), By End Users, 2022 & 2032

Figure 97: Latin America Vs. Brazil Growth Comparison

Figure 98: Mexico Market Share Analysis (%), By Test Type, 2022 & 2032

Figure 99: Mexico Market Share Analysis (%), By Indication, 2022 & 2032

Figure 100: Mexico Market Share Analysis (%), By End Users, 2022 & 2032

Figure 101: Latin America Vs. Mexico Growth Comparison

Figure 102: Argentina Market Share Analysis (%), By Test Type, 2022 & 2032

Figure 103: Argentina Market Share Analysis (%), By Indication, 2022 & 2032

Figure 104: Argentina Market Share Analysis (%), By End Users, 2022 & 2032

Figure 105: Latin America Vs. Argentina Growth Comparison

Figure 106: U.K. Market Share Analysis (%), By Test Type, 2022 & 2032

Figure 107: U.K. Market Share Analysis (%), By Indication, 2022 & 2032

Figure 108: U.K. Market Share Analysis (%), By End Users, 2022 & 2032

Figure 109: Europe Vs. U.K. Growth Comparison

Figure 110: Germany Market Share Analysis (%), By Test Type, 2022 & 2032

Figure 111: Germany Market Share Analysis (%), By Indication, 2022 & 2032

Figure 112: Germany Market Share Analysis (%), By End Users, 2022 & 2032

Figure 113: Europe Vs. Germany Growth Comparison

Figure 114: Italy Market Share Analysis (%), By Test Type, 2022 & 2032

Figure 115: Italy Market Share Analysis (%), By Indication, 2022 & 2032

Figure 116: Italy Market Share Analysis (%), By End Users, 2022 & 2032

Figure 117: Europe Vs. Italy Growth Comparison

Figure 118: France Market Share Analysis (%), By Test Type, 2022 & 2032

Figure 119: France Market Share Analysis (%), By Indication, 2022 & 2032

Figure 120: France Market Share Analysis (%), By End Users, 2022 & 2032

Figure 121: Europe Vs. France Growth Comparison

Figure 122: Spain Market Share Analysis (%), By Test Type, 2022 & 2032

Figure 123: Spain Market Share Analysis (%), By Indication, 2022 & 2032

Figure 124: Spain Market Share Analysis (%), By End Users, 2022 & 2032

Figure 125: Europe Vs. Spain Growth Comparison

Figure 126: Russia Market Share Analysis (%), By Test Type, 2022 & 2032

Figure 127: Russia Market Share Analysis (%), By Indication, 2022 & 2032

Figure 128: Russia Market Share Analysis (%), By End Users, 2022 & 2032

Figure 129: Europe Vs. Russia Growth Comparison

Figure 130: India Market Share Analysis (%), By Test Type, 2022 & 2032

Figure 131: India Market Share Analysis (%), By Indication, 2022 & 2032

Figure 132: India Market Share Analysis (%), By End Users, 2022 & 2032

Figure 133: South Asia Vs. India Growth Comparison

Figure 134: Thailand Market Share Analysis (%), By Test Type, 2022 & 2032

Figure 135: Thailand Market Share Analysis (%), By Indication, 2022 & 2032

Figure 136: Thailand Market Share Analysis (%), By End Users, 2022 & 2032

Figure 137: South Asia Vs. Thailand Growth Comparison

Figure 138: Malaysia Market Share Analysis (%), By Test Type, 2022 & 2032

Figure 139: Malaysia Market Share Analysis (%), By Indication, 2022 & 2032

Figure 140: Malaysia Market Share Analysis (%), By End Users, 2022 & 2032

Figure 141: South Asia Vs. Malaysia Growth Comparison

Figure 142: Indonesia Market Share Analysis (%), By Test Type, 2022 & 2032

Figure 143: Indonesia Market Share Analysis (%), By Indication, 2022 & 2032

Figure 144: Indonesia Market Share Analysis (%), By End Users, 2022 & 2032

Figure 145: South Asia Vs. Indonesia Growth Comparison

Figure 146: China Market Share Analysis (%), By Test Type, 2022 & 2032

Figure 147: China Market Share Analysis (%), By Indication, 2022 & 2032

Figure 148: China Market Share Analysis (%), By End Users, 2022 & 2032

Figure 149: East Asia Vs. China Growth Comparison

Figure 150: Japan Market Share Analysis (%), By Test Type, 2022 & 2032

Figure 151: Japan Market Share Analysis (%), By Indication, 2022 & 2032

Figure 152: Japan Market Share Analysis (%), By End Users, 2022 & 2032

Figure 153: East Asia Vs. Japan Growth Comparison

Figure 154: South Korea Market Share Analysis (%), By Test Type, 2022 & 2032

Figure 155: South Korea Market Share Analysis (%), By Indication, 2022 & 2032

Figure 156: South Korea Market Share Analysis (%), By End Users, 2022 & 2032

Figure 157: East Asia Vs. South Korea Growth Comparison

Figure 158: Australia Market Share Analysis (%), By Test Type, 2022 & 2032

Figure 159: Australia Market Share Analysis (%), By Indication, 2022 & 2032

Figure 160: Australia Market Share Analysis (%), By End Users, 2022 & 2032

Figure 161: Oceania Vs. Australia Growth Comparison

Figure 162: New Zealand Market Share Analysis (%), By Test Type, 2022 & 2032

Figure 163: New Zealand Market Share Analysis (%), By Indication, 2022 & 2032

Figure 164: New Zealand Market Share Analysis (%), By End Users, 2022 & 2032

Figure 165: Oceania Vs. New Zealand Growth Comparison

Figure 166: Turkey Market Share Analysis (%), By Test Type, 2022 & 2032

Figure 167: Turkey Market Share Analysis (%), By Indication, 2022 & 2032

Figure 168: Turkey Market Share Analysis (%), By End Users, 2022 & 2032

Figure 169: MEA Vs. Turkey Growth Comparison

Figure 170: GCC Market Share Analysis (%), By Test Type, 2022 & 2032

Figure 171: GCC Market Share Analysis (%), By Indication, 2022 & 2032

Figure 172: GCC Market Share Analysis (%), By End Users, 2022 & 2032

Figure 173: MEA Vs. GCC Growth Comparison

Figure 174: South Africa Market Share Analysis (%), By Test Type, 2022 & 2032

Figure 175: South Africa Market Share Analysis (%), By Indication, 2022 & 2032

Figure 176: South Africa Market Share Analysis (%), By End Users, 2022 & 2032

Figure 177: MEA vs. South Africa Growth Comparison

Need specific information?

Request Customization

Explore Healthcare Insights

View Reports

Recommendations

Healthcare

Colorectal Cancer Molecular Diagnostics Market

Published : January 2019

Healthcare

Early-Stage Lung Cancer Diagnostics Therapy Market

Published : December 2018

Healthcare

Cancer Tissue Diagnostics Market

Published : March 2021

Healthcare

Brain Cancer Diagnostics Market

Published : December 2016

Google translate

Cancer Diagnostics Market